Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress
LEQEMBI IQLIK® Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
LEQEMBI IQLIK® Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
FDA Approves LEQEMBI IQLIK® Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® 2026
Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol Phase 3 Study Results in Systemic Lupus Erythematosus
Topline Results from Phase 2 CELIA Study of Diranersen : First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease
NevGold Appoints Dale Found as CFO, Current CFO Bob McKnight Transitions to VP Engineering Studies To Support Next Project Development Phase
Skyharbour Files Independent NI 43-101 Technical Reports on its Co-Flagship Moore and Russell Lake Uranium Projects, Saskatchewan
Red Metal Resources Reports First Ore Delivery from Farellon Ahead of Schedule, Launching Non-Dilutive Royalty Revenue
